A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Orphanet Journal of Rare Diseases Année : 2021

A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases

1 APHM - Assistance Publique - Hôpitaux de Marseille
2 Groupe hospitalier Pellegrin
3 CHU Pitié-Salpêtrière [AP-HP]
4 Centre de recherche en Myologie – U974 SU-INSERM
5 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
6 TCDV - Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046
7 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
8 Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL]
9 TIMONE - Hôpital de la Timone [CHU - APHM]
10 AMU - Aix Marseille Université
11 Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
12 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
13 Hôpital Raymond Poincaré [AP-HP]
14 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest
15 CHU Henri Mondor [Créteil]
16 Hôpital Cochin [AP-HP]
17 PARCC (UMR_S 970/ U970) - Paris-Centre de Recherche Cardiovasculaire
18 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
19 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
20 CHU Bordeaux
21 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
22 END-ICAP - Handicap neuromusculaire : Physiopathologie, Biothérapie et Pharmacologies appliquées
23 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
24 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
25 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
26 Hôpital Necker - Enfants Malades [AP-HP]
27 AFM-Téléthon - Association française contre les myopathies
Guilhem Sole
Shahram Attarian
  • Fonction : Auteur
  • PersonId : 1042088

Résumé

Background: Due to their health condition, patients with neuromuscular diseases (NMD) are at greater risk of developing serious complications with COVID-19. The objective of this study was to analyze the prevalence of COVID-19 among NMD patients and the risk factors for its impact and severity during the first wave of the pandemic. Clinical data were collected from NMD-COVID-19 patients, between March 25, 2020 and May 11, 2020 in an anonymous survey carried out by expert physicians from the French Health Care Network Filnemus. Results: Physicians reported 84 patients, including: 34 with myasthenia gravis, 27 with myopathy and 23 with neuropathy. COVID-19 had no effect on NMD for 48 (58%) patients and 48 (58%) patients developed low COVID-19 severity. COVID-19 caused the death of 9 (11%) NMD patients. Diabetic patients were at greater risk of dying. Patients with diabetes, hypertension or severe forms of NMD had a higher risk of developing a moderate or severe form of COVID-19. In our cohort, corticosteroids and other immunosuppressants were not significantly associated with higher COVID-19 severity for acquired NMD. Conclusion: During this period, a small percentage of French NMD patients was affected by COVID-19 compared to the general French population and COVID-19 had a limited short-term effect on them. Diabetes, hypertension and a severe degree of NMD were identified as risk factors of unfavorable outcome following COVID-19. Conversely, in our cohort of patients with acquired NMD, corticosteroids or other immunosuppressants did not appear to be risk factors for more severe COVID-19.
Fichier principal
Vignette du fichier
BPH_OJRD_2021_Pisella.pdf (870.64 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03470914 , version 1 (08-12-2021)

Licence

Identifiants

Citer

Lucie Isoline Pisella, Sara Fernandes, Guilhem Sole, Tanya Stojkovic, Celine Tard, et al.. A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases. Orphanet Journal of Rare Diseases, 2021, 16 (1), pp.450. ⟨10.1186/s13023-021-02090-y⟩. ⟨hal-03470914⟩
127 Consultations
48 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More